Igf1 Lr3 vs Igf1 Des
Which Is Right for You? Complete Comparison (2026)
Detailed comparison of IGF-1 LR3 and IGF-1 DES. Understand half-lives, localized vs systemic muscle growth, and optimal protocol timing for bodybuilding.
Igf1 Lr3 vs Igf1 Des: At a Glance
- ✓Primary mediator of growth hormone anabolic effects
- ✓Produced mainly by the liver in response to GH stimulation
- ✓Promotes muscle protein synthesis and bone growth
- ✓Inhibits protein breakdown (anti-catabolic)
- ✓LR3 variant has extended half-life and greater potency
- ✓Primary mediator of growth hormone anabolic effects
- ✓Produced mainly by the liver in response to GH stimulation
- ✓Promotes muscle protein synthesis and bone growth
- ✓Inhibits protein breakdown (anti-catabolic)
- ✓LR3 variant has extended half-life and greater potency
Detailed Comparison
| Feature | Igf1 Lr3 | Igf1 Des |
|---|---|---|
| Mechanism | Growth factor | Growth factorBest |
| Dosing | IGF-1 LR3: 20-60 mcg SC daily; Des(1-3): 50-100 mcg | IGF-1 LR3: 20-60 mcg SC daily; Des(1-3): 50-100 mcg |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Half-life | Native: ~20 hours; LR3: ~20-30 hours | Native: ~20 hours; LR3: ~20-30 hours |
| FDA Status | IGF-1 FDA-approved (Increlex) for severe GH insensitivity | IGF-1 FDA-approved (Increlex) for severe GH insensitivity |
| Key Trial | Laron Z. Mol Pathol 2001 — IGF-1 review | Laron Z. Mol Pathol 2001 — IGF-1 review |
| Side Effects | Hypoglycemia, joint pain, potential tumor growth risk | Hypoglycemia, joint pain, potential tumor growth risk |
Which Should You Choose?
IGF-1 (Insulin-like Growth Factor) (growth factor) and IGF-1 (Insulin-like Growth Factor) (growth factor) serve different clinical roles despite both being in the Growth factor space. IGF-1 (Insulin-like Growth Factor) anabolic growth factor primarily produced by the liver in response to gh. IGF-1 (Insulin-like Growth Factor) anabolic growth factor primarily produced by the liver in response to gh.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Igf1 Lr3 and Igf1 Des
Choosing between Igf1 Lr3 and Igf1 Des depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Igf1 Lr3 and Igf1 Des is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Igf1 Lr3 vs Igf1 Des: Frequently Asked Questions
IGF-1 (Insulin-like Growth Factor) is a growth factor while IGF-1 (Insulin-like Growth Factor) is a growth factor. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
IGF-1 (Insulin-like Growth Factor) works as a growth factor (IGF-1 LR3: 20-60 mcg SC daily; Des(1-3): 50-100 mcg), while IGF-1 (Insulin-like Growth Factor) is a growth factor (IGF-1 LR3: 20-60 mcg SC daily; Des(1-3): 50-100 mcg). They have different half-lives (Native: ~20 hours; LR3: ~20-30 hours vs Native: ~20 hours; LR3: ~20-30 hours), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Igf1 Lr3 or Igf1 Des in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.